Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ripretinib · Qinlock, DCC-2618

Small molecule · Inhibitor of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor alpha (PDGFRA) · developed by Deciphera Pharms

Approved FDA, May 2020
2 Registered trials

What is Ripretinib?

Ripretinib is an orally bioavailable tyrosine kinase inhibitor that binds the switch pocket of wild-type and mutated KIT and PDGFRA, preventing their activation and blocking tumor cell signaling. It also inhibits several other kinases, including VEGFR2, TIE2 and PDGFRB. It is used in gastrointestinal stromal tumor (GIST).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Qinlock, DCC-2618
Drug type
Small molecule
Targets
KIT proto-oncogene receptor tyrosine kinase (KIT), platelet derived growth factor receptor alpha (PDGFRA), PDGFRB (secondary target), TIE2 (TEK) (secondary target), VEGFR2 (KDR) (secondary target), BRAF (secondary target)
Mechanism
Inhibitor of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor alpha (PDGFRA)
Pathways
tumor cell proliferation signaling
Therapy area
Oncology
Developer
Deciphera Pharms
In trials of
ZLAB
FDA status
Approved as Qinlock (May 15, 2020), NDA213973 · FDA label
UNII
9XW757O13D

✅ FDA-approved uses

From the indications section of the FDA label (version of May 12, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04633122 Phase 2 Gastrointestinal Stromal Tumor(GIST) Completed ZLAB
NCT04282980 Phase 2 Gastrointestinal Stromal Tumors Completed ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastrointestinal Stromal Tumors

Other drugs acting on KIT / PDGFRA

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.